Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, United States of America.
PLoS One. 2012;7(8):e42609. doi: 10.1371/journal.pone.0042609. Epub 2012 Aug 6.
The recent development of a Hepatitis C virus (HCV) infectious virus cell culture model system has facilitated the development of whole-virus screening assays which can be used to interrogate the entire virus life cycle. Here, we describe the development of an HCV growth assay capable of identifying inhibitors against all stages of the virus life cycle with assay throughput suitable for rapid screening of large-scale chemical libraries. Novel features include, 1) the use of an efficiently-spreading, full-length, intergenotypic chimeric reporter virus with genotype 1 structural proteins, 2) a homogenous assay format compatible with miniaturization and automated liquid-handling, and 3) flexible assay end-points using either chemiluminescence (high-throughput screening) or Cellomics ArrayScan™ technology (high-content screening). The assay was validated using known HCV antivirals and through a large-scale, high-throughput screening campaign that identified novel and selective entry, replication and late-stage inhibitors. Selection and characterization of resistant viruses provided information regarding inhibitor target and mechanism. Leveraging results from this robust whole-virus assay represents a critical first step towards identifying inhibitors of novel targets to broaden the spectrum of antivirals for the treatment of HCV.
最近开发的丙型肝炎病毒 (HCV) 感染性病毒细胞培养模型系统促进了全病毒筛选检测方法的发展,这些方法可用于研究整个病毒生命周期。在此,我们描述了一种 HCV 生长检测方法的开发,该方法能够鉴定针对病毒生命周期各个阶段的抑制剂,具有适合大规模化学文库快速筛选的检测通量。新的特点包括:1)使用具有基因型 1 结构蛋白的高效传播、全长、基因间嵌合报告病毒;2)与微型化和自动化液体处理兼容的均质检测格式;3)使用化学发光(高通量筛选)或 Cellomics ArrayScan™ 技术(高内涵筛选)灵活的检测终点。该检测方法通过使用已知的 HCV 抗病毒药物进行验证,并通过大规模高通量筛选活动鉴定了新型和选择性的进入、复制和晚期抑制剂。抗性病毒的选择和鉴定提供了有关抑制剂靶标和机制的信息。利用该强大的全病毒检测方法的结果代表着朝着鉴定新型靶标抑制剂迈出的关键第一步,以扩大治疗 HCV 的抗病毒药物谱。